BR112013012671B1 - Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína - Google Patents

Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína Download PDF

Info

Publication number
BR112013012671B1
BR112013012671B1 BR112013012671-0A BR112013012671A BR112013012671B1 BR 112013012671 B1 BR112013012671 B1 BR 112013012671B1 BR 112013012671 A BR112013012671 A BR 112013012671A BR 112013012671 B1 BR112013012671 B1 BR 112013012671B1
Authority
BR
Brazil
Prior art keywords
seq
bip
sequence
signal sequence
protein
Prior art date
Application number
BR112013012671-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013012671A2 (pt
Inventor
Hung Do
Original Assignee
Amicus Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc filed Critical Amicus Therapeutics, Inc
Publication of BR112013012671A2 publication Critical patent/BR112013012671A2/pt
Publication of BR112013012671B1 publication Critical patent/BR112013012671B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013012671-0A 2010-11-22 2011-11-22 Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína BR112013012671B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
US61/415,926 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (2)

Publication Number Publication Date
BR112013012671A2 BR112013012671A2 (pt) 2016-10-11
BR112013012671B1 true BR112013012671B1 (pt) 2022-03-03

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012671-0A BR112013012671B1 (pt) 2010-11-22 2011-11-22 Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP2643468B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK2643468T3 (enExample)
ES (2) ES2829199T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3164492T1 (sl) * 2014-07-03 2020-02-28 F. Hoffmann-La Roche Ag Sistem polipeptidne ekspresije
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JP2021505135A (ja) * 2017-11-30 2021-02-18 アミカス セラピューティックス インコーポレイテッド Ｃｄｋｌ５発現変異体及びｃｄｋｌ５融合タンパク質
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
BR112020021962A2 (pt) 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US11097015B2 (en) 2018-10-10 2021-08-24 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN120519489A (zh) * 2018-12-19 2025-08-22 维萨梅布有限公司 编码蛋白质的rna
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
EP3980548A4 (en) * 2019-04-30 2023-09-06 The Trustees of The University of Pennsylvania Compositions useful for treatment of pompe disease
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1133517E (pt) * 1998-11-24 2009-08-12 Bristol Myers Squibb Co Distribuição intracelular direccionada de compostos através da proteína de choque térmico de 70 kda
CA2545053C (en) * 2003-11-06 2016-04-19 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
JP2009533364A (ja) * 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法

Also Published As

Publication number Publication date
SI2643468T1 (sl) 2018-10-30
ES2829199T3 (es) 2021-05-31
ES2687415T3 (es) 2018-10-25
KR101984318B1 (ko) 2019-05-31
PT2643468T (pt) 2018-10-11
CN103328649B (zh) 2016-06-22
WO2012071422A2 (en) 2012-05-31
DK3461905T3 (da) 2020-11-02
WO2012071422A3 (en) 2012-08-02
CA2818689A1 (en) 2012-05-31
SMT201800466T1 (it) 2018-11-09
LT2643468T (lt) 2018-09-10
EP3461905A1 (en) 2019-04-03
EP2643468A4 (en) 2014-12-24
HUE039070T2 (hu) 2018-12-28
BR112013012671A2 (pt) 2016-10-11
DK2643468T3 (en) 2018-09-24
US9279007B2 (en) 2016-03-08
EP2643468B1 (en) 2018-07-04
RS57601B1 (sr) 2018-11-30
CN103328649A (zh) 2013-09-25
HRP20181315T1 (hr) 2018-10-19
US20140045216A1 (en) 2014-02-13
EP3461905B1 (en) 2020-08-05
EP2643468A2 (en) 2013-10-02
CY1121049T1 (el) 2019-12-11
JP2014503198A (ja) 2014-02-13
PL2643468T3 (pl) 2018-11-30
CA2818689C (en) 2021-09-21
KR20190060888A (ko) 2019-06-03
KR20130121878A (ko) 2013-11-06

Similar Documents

Publication Publication Date Title
BR112013012671B1 (pt) Sequência sinal de polipeptídio, proteína de fusão e vetor de expressão de proteína
Jiang et al. Integral membrane protein sorting to vacuoles in plant cells: evidence for two pathways
Van Loon et al. Transport of proteins to the mitochondrial intermembrane space: the ‘matrix‐targeting’and the ‘sorting’domains in the cytochrome c1 presequence.
Wahlberg et al. Multiple determinants direct the orientation of signal–anchor proteins: the topogenic role of the hydrophobic signal domain
Flores-Pérez et al. Molecular chaperone involvement in chloroplast protein import
Riggs Expression and purification of recombinant proteins by fusion to maltose-binding protein
US6207420B1 (en) Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in Escherichia coli
Lee et al. Membrane topology of transmembrane proteins: determinants and experimental tools
JPH03504597A (ja) インスリン様成長因子活性の強化および阻害方法
BR112014004830B1 (pt) Célula de levedura geneticamente modificada, seu uso e método para produzir uma proteína ou polipeptídio recombinante de interesse
Dou et al. Type II transmembrane domain hydrophobicity dictates the cotranslational dependence for inversion
Ng et al. Protein translocation across the endoplasmic reticulum
Zocchi et al. Expression and purification of a recombinant avidin with a lowered isoelectric point in Pichia pastoris
JP6064915B2 (ja) 発現ベクターおよび蛋白質の製造方法
US7741075B2 (en) Pichia pastoris PIR1 secretion signal peptide for recombinant protein expression and Pichia pastoris PIR1 and PIR2 anchor domain peptides for recombinant surface display
Bass et al. Application of the E. coli trp promoter
Hassan et al. The trafficking of prosaposin (SGP‐1) and GM2AP to the lysosomes of TM4 sertoli cells is mediated by sortilin and monomeric adaptor proteins
Bercovich-Kinori et al. Co-translational membrane association of the Escherichia coli SRP receptor
CN103483423B (zh) 一种人工合成的信号肽及其应用
HK40006980A (en) Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins
Eskridge et al. The NH2 terminus of preproinsulin directs the translocation and glycosylation of a bacterial cytoplasmic protein by mammalian microsomal membranes.
HK1189913B (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
HK1189913A (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
US12331091B2 (en) Chimeric signal peptides for protein production
Riggs Detection and Isolation of Recombinant Protein Based on Binding Affinity Reporter: Maltose Binding Protein

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AMICUS THERAPEUTICS, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.